Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lindsay Angus

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Cancers|September 9, 2023
Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER SignalingLindsay Angus, Marcel Smid, Saskia M Wilting, et al.
The American Journal of Surgical Pathology|July 9, 2019
Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 ResultsSuzanne C van Es, Bert van der Vegt, Frederike Bensch, et al.
The Journal of Molecular Diagnostics : JMD|October 9, 2018
An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNASilvia R Vitale, Anieta M Sieuwerts, Nick Beije, et al.
Clinical Epigenetics|October 21, 2021
High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragmentsTeoman Deger, Ruben G Boers, Vanja de Weerd, et al.
Molecular Oncology|July 28, 2019
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancerErik J van Helden, Lindsay Angus, C Willemien Menke-van der Houven van Oordt, et al.
Diagnostics (Basel, Switzerland)|May 4, 2026
Circulating Tumor Cells Enhance Prognostic Stratification Beyond ER Assessment by Biopsy or FES-PET in Endocrine-Treated Metastatic Breast CancerBertha Eisses, Lindsay Angus, Evelien J M Kuip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2025
Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal CancerSophie L Gerritse, Erik J van Helden, Anne I J Arens, et al.
Nature Genetics|October 2, 2019
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequenciesLindsay Angus, Marcel Smid, Saskia M Wilting, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 8, 2019
Lesion detection by [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinomaSarah R Verhoeff, Suzanne C van Es, Eline Boon, et al.
JAMA Oncology|April 16, 2026
18F-Fluorodeoxyglucose Positron Emission Tomography for Estimating Outcomes After Initial Treatment for Metastatic Breast Cancer: A Nonrandomized Clinical Cohort TrialJasper J L van Geel, Bertha Eisses, Sjoerd G Elias, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Cancers|September 9, 2023
Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER SignalingLindsay Angus, Marcel Smid, Saskia M Wilting, et al.
The American Journal of Surgical Pathology|July 9, 2019
Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 ResultsSuzanne C van Es, Bert van der Vegt, Frederike Bensch, et al.
The Journal of Molecular Diagnostics : JMD|October 9, 2018
An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNASilvia R Vitale, Anieta M Sieuwerts, Nick Beije, et al.
Clinical Epigenetics|October 21, 2021
High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragmentsTeoman Deger, Ruben G Boers, Vanja de Weerd, et al.
Molecular Oncology|July 28, 2019
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancerErik J van Helden, Lindsay Angus, C Willemien Menke-van der Houven van Oordt, et al.
Diagnostics (Basel, Switzerland)|May 4, 2026
Circulating Tumor Cells Enhance Prognostic Stratification Beyond ER Assessment by Biopsy or FES-PET in Endocrine-Treated Metastatic Breast CancerBertha Eisses, Lindsay Angus, Evelien J M Kuip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2025
Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal CancerSophie L Gerritse, Erik J van Helden, Anne I J Arens, et al.
Nature Genetics|October 2, 2019
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequenciesLindsay Angus, Marcel Smid, Saskia M Wilting, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 8, 2019
Lesion detection by [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinomaSarah R Verhoeff, Suzanne C van Es, Eline Boon, et al.
JAMA Oncology|April 16, 2026
18F-Fluorodeoxyglucose Positron Emission Tomography for Estimating Outcomes After Initial Treatment for Metastatic Breast Cancer: A Nonrandomized Clinical Cohort TrialJasper J L van Geel, Bertha Eisses, Sjoerd G Elias, et al.
Pageof 3